Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
NHS England has approved the drug mirvetuximab soravtansine for patients with chemotherapy-resistant ovarian cancer. This marks the first new treatment for this specific condition in over two decades.
Why it matters
This approval provides a critical new option for hundreds of women annually who have exhausted standard treatment pathways for advanced ovarian cancer.
A coloured scanning electron micrograph of ovarian cancer cells. Ovarian is the 18th most common type of cancer globally. Photograph: Science Photo Library/Alamy View image in fullscreen A coloured scanning electron micrograph of ovarian cancer cells. Ovarian is the 18th most common type of cancer globally. Photograph: Science Photo Library/Alamy Ovarian cancer Life-prolonging drug for advanced ovarian cancer gets go-ahead in England Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years
The article provides factual reporting on medical policy and health outcomes.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in